Mitchell Leslie Ann, Leong Roger, Rosenke Karla A
Department of Pathology, University of British Columbia, BC Research Institute for Children's and Women's Health, 950 West 28th Avenue, Vancouver, BC V5Z 4H4, Canada.
J Med Microbiol. 2001 Jul;50(7):627-635. doi: 10.1099/0022-1317-50-7-627.
Immune recognition of recombinant parvovirus B19 non-structural (rNS1) protein was studied by immunoblot and lymphoproliferative assays in blood from the following B19 seropositive groups: B19 infected (n = 14), B19 exposed but non-infected (n = 16), other illness with rash (n = 3), chronic arthropathy of unknown aetiology (n = 4) and healthy controls (n = 7). Sera from 11 B19 seronegative subjects were also studied. Sera collected at initial diagnosis or at the time of accidental B19 exposure in pregnancy were tested for NS1 antibody and evidence of B19 DNA by nested PCR. Follow-up specimens were obtained 3-12 months later for serological, PCR and proliferation studies. B19 DNA was detected sporadically in early specimens and in one follow-up specimen from a subject who developed chronic arthropathy after B19 infection. There was no correlation with development of arthropathy. NS1-specific IgG was detected in early sera from B19-infected and exposed subjects but to a lesser degree in follow-up specimens, and in only one healthy control serum. No correlation with the presence of NS1-specific antibodies was found with development of acute or chronic arthropathy. Although lymphocyte proliferation in response to stimulation with rNS1 in vitro occurred at a higher frequency in patients who developed acute and chronic joint manifestations after B19 infection, suggesting an association with this outcome, NS1-reactive lymphocytes were also found in three B19 seronegative patients, two of whom had recently been exposed to B19 but had no illness. Hence, immune recognition of NS1 may be more indicative of recent infection with, or exposure to, parvovirus B19 than associated with development of arthropathy as previously reported.
通过免疫印迹和淋巴细胞增殖试验，对以下B19血清阳性组血液中的重组细小病毒B19非结构（rNS1）蛋白的免疫识别进行了研究：B19感染组（n = 14）、B19暴露但未感染组（n = 16）、其他有皮疹疾病组（n = 3）、病因不明的慢性关节病组（n = 4）以及健康对照组（n = 7）。还研究了11名B19血清阴性受试者的血清。在初次诊断时或孕期意外暴露于B19时采集的血清，检测NS1抗体并通过巢式PCR检测B19 DNA证据。3 - 12个月后获取随访标本进行血清学、PCR和增殖研究。在早期标本以及一名B19感染后发生慢性关节病受试者的一份随访标本中偶尔检测到B19 DNA。这与关节病的发生无关。在B19感染和暴露受试者的早期血清中检测到NS1特异性IgG，但在随访标本中程度较轻，且仅在一份健康对照血清中检测到。未发现NS1特异性抗体的存在与急性或慢性关节病的发生相关。尽管在B19感染后出现急性和慢性关节表现的患者中，体外rNS1刺激引起的淋巴细胞增殖频率较高，提示与该结果有关联，但在3名B19血清阴性患者中也发现了NS1反应性淋巴细胞，其中2名患者近期暴露于B19但未患病。因此，与先前报道的与关节病发生相关相比，NS1的免疫识别可能更表明近期感染或暴露于细小病毒B19。
